Withings announced today that it received approximately $22.5 million in investment and support for a new initiative from the French government.
Through the France 2030 initiative, Withings is launching “Project Deep” (DEvice as a hEalth Prevention platform). The initiative aims to utilize cutting-edge AI and medical device innovation. It wants to advance the early detection and prevention of cardiometabolic diseases. The company wants to accelerate the digital and prevention transition of healthcare systems around the world.
Project DEEP intends to develop advanced, non-invasive medical devices capable of detecting cardiometabolic pathologies earlier. France 2030, a $56.6 billion initiative, aims to shape a sustainable and innovative future for France.
Withings said Project DEEP represents a milestone in the fight against conditions like diabetes, hypertension, AFib and neuropathies. These conditions strain healthcare systems, but early detection and prevention could address challenges before they lead to serious complications. Such complications could include stroke, myocardial infarction and amputations.
The company offers a portfolio of connected medical devices. That includes smart scales, blood pressure monitors, watches, sleep analyzers and urine analyzers. Combining AI with this ecosystem enables scalable, proactive care tailored to individual health profiles.
“With the surge in cardiometabolic diseases burdening healthcare systems, technological innovation and AI research are pivotal in transitioning to a preventive care model,” said Eric Carreel, chair and founder of Withings. “France 2030’s support underscores the importance of empowering French companies like Withings to lead globally in this transformation. Over the next five years, Project DEEP will spearhead Withings’ R&D efforts, enhancing our existing products and paving the way for groundbreaking medical devices and solutions we have yet to imagine.”